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Abstract
Background:  The use of diagnostic 18F-fluorodeoxyglucose (18F-FDG) positron emission
tomography/computed tomography (PET/CT) imaging for the staging, restaging, and treatment
monitoring of melanoma patients has become a well-recognized standard of care. It plays a key role
in detecting sites of occult disease and is widely utilized in the medical and surgical planning of such
patients. In the current report, we describe an innovative multimodality approach of perioperative
18F-FDG PET/CT imaging, intraoperative 18F-FDG handheld gamma probe detection, and
intraoperative ultrasound for tumor localization and verification of resection of all sites of
hypermetabolic tumor foci in a case of occult recurrent metastatic melanoma.
Case presentation: This report discusses a case of occult recurrent metastatic melanoma,
isolated to three separate sites within the subcutaneous tissues of the left thigh region, which was
not clinically apparent but was found on diagnostic restaging whole body 18F-FDG PET/CT scan
utilizing an intravenous injection of 14.8 mCi 18F-FDG. Then, on the day of surgery, the patient
received an intravenous injection of 12.8 mCi 18F-FDG. A multimodality approach of intraoperative
handheld gamma probe detection, intraoperative ultrasound tumor localization, specimen PET/CT
imaging, and postoperative PET/CT imaging was utilized for accomplishing and verifying the excision
of all three sites of occult recurrent metastatic melanoma within the left thigh region.
Conclusion: This innovative multimodality approach of perioperative 18F-FDG PET/CT imaging,
intraoperative  18F-FDG handheld gamma probe detection, and intraoperative ultrasound is
promising combined technology for aiding in tumor localization and verification of excision and may
ultimately impact positively upon long-term outcome of selected patients.
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Background
In the year 2007, within the United State alone, it is esti-
mated that approximately 60,000 cases of melanoma will
be diagnosed and approximately 8,100 people will die of
this disease [1]. Early detection and appropriate surgical
intervention with wide excision of the primary lesion and
evaluation of suspect lymph node basins remain the hall-
marks of the initial management strategy for melanoma
[2]. Still, the risk of developing both locoregional recur-
rence and distant recurrence remains a legitimate concern
and consequently portends a poor prognostic outcome
[3]. Despite advances in systemic therapies for metastatic
melanoma, surgical resection of limited recognizable
recurrent disease is considered appropriate and is often
the preferred management strategy [2].
Diagnostic  18F-fluorodeoxyglucose (18F-FDG) positron
emission tomography/computed tomography (PET/CT)
imaging has become a well-established method for stag-
ing, restaging, and monitoring response to therapy of
melanoma patients, and is widely accepted as a standard
of care [2,4,5]. In this regard, this technology plays a key
role in detecting sites of occult disease and is widely uti-
lized in the medical and surgical planning of such patients
[2,4-6].
The current application of 18F-FDG PET/CT imaging for
melanoma patients is generally that of diagnostic image
acquisition at the time of the original evaluation in those
individuals considered at an elevated risk for regional
and/or distant disease. In those instances when regional
and/or distant disease can potentially be surgically
approached, this current practice of diagnostic image
acquisition at the time of the original patient evaluation
provides only a static roadmap for guiding the surgical
approach, but does not provide the surgeon with real-time
intraoperative information on tumor location and verifi-
cation of tumor resection. Recently, the application of
intraoperative gamma probe detection in melanoma
patients after preoperative injection of an intravenous
dose of 18F-FDG has been reported by several groups of
investigators [7-11]. Furthermore, the specific application
of a combined approach of preoperative 18F-FDG PET/CT
imaging and intraoperative gamma probe detection for a
case of recurrent melanoma has been recently reported by
Carrera et al [11]. Applying this approach to recurrent
melanoma, as well as further development and refine-
ment of such innovative approaches for perioperatively
detecting and intraoperatively directing the surgeon in
identifying and removing all sites of disease may ulti-
mately translate into improved long-term outcome of
selected patients.
In the current Technical Innovations report, we describe
an innovative multimodality approach of perioperative
18F-FDG PET/CT imaging, intraoperative 18F-FDG hand-
held gamma probe detection, and intraoperative ultra-
sound for tumor localization and verification of resection
of all sites of hypermetabolic activity in a case of occult
recurrent metastatic melanoma.
Case presentation
The case presented is that of a 50 year-old Caucasian
female with isolated recurrence of metastatic melanoma
to the subcutaneous tissues of her left thigh. Ten years
prior to her current presentation, she underwent a wide
excision and skin grafting of her left distal thigh region
and a superficial left groin lymph node dissection for a 2.3
mm malignant cutaneous melanoma with 22 negative
lymph nodes. She received no adjuvant therapy and sub-
sequently continued routine follow-up by her surgeon.
Twenty-five months prior to her current presentation, she
developed two skin nodules located approximately 4 cm
distal to the previous skin graft on her distal thigh region.
A wide excision of her left distal thigh region was subse-
quently performed. A diagnostic whole body 18F-FDG PET
scan was performed, utilizing an intravenous injection of
13.9 mCi 18F-FDG, that revealed a solitary hypermetabolic
focus within the anteriomedial left mid thigh region (peak
SUV of 40.1) which was not palpable on clinical examina-
tion. No other hypermetabolic foci were identified else-
where in her body. As a result, the patient subsequently
(23 months prior to her current presentation) underwent
isolated left lower extremity hyperthermic limb perfusion
with melphalan and a concomitant left deep groin lymph
node dissection.
A six-month follow-up (17 months prior to her current
presentation) diagnostic whole body 18F-FDG PET/CT
scan was performed, utilizing an intravenous injection of
16.3 mCi 18F-FDG, and redemonstrated a solitary hyper-
metabolic focus within the subcutaneous tissues of the
anteriomedial left mid thigh region, with a peak SUV of
7.6. No other hypermetabolic foci were identified else-
where in her body. Subsequently (15 months prior to her
current presentation), CT guided wire localization and
wide excision of the nonpalpable subcutaneous focus of
disease in her anteriomedial left mid thigh region was per-
formed.
The patient continued routine follow-up by her surgeon.
One month prior to her current presentation, the patient
underwent a routine follow-up diagnostic restaging whole
body 18F-FDG PET/CT scan (Figure 1) on a Siemens Bio-
graph 16 PET/CT unit (Knoxville, TN, USA) utilizing an
intravenous injection of 14.8 mCi 18F-FDG. The scan
demonstrated three foci of hypermetabolic activity within
the subcutaneous tissues of the anterior left thigh region.
Two closely approximated hypermetabolic foci (peak SUVWorld Journal of Surgical Oncology 2008, 6:1 http://www.wjso.com/content/6/1/1
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of 25.3) were located in the subcutaneous tissues of the
anteriomedial left mid thigh region and one hypermeta-
bolic focus (peak SUV of 3.4) was located in the subcuta-
neous tissues of the anterior lower one-third of the left
thigh region. No other hypermetabolic foci were identi-
fied elsewhere in her body. On clinical exam, no visible or
palpable abnormalities were noted in the left thigh region
or elsewhere.
On the day of surgery, a dose of 12.8 mCi 18F-FDG was
injected intravenously into a peripheral vein at approxi-
mately 80 minutes prior to the start time of the surgical
procedure, as per our 18F-FDG and PET/CT protocols pre-
viously described [12,13]. The patient was subsequently
taken to the operating room. Intraoperatively, a handheld
gamma probe (Neoprobe neo2000 unit, Neoprobe Cor-
poration, Dublin, Ohio, USA) was used to attempt locali-
zation of the three areas of increased 18F-FDG uptake
within the left thigh region. Initially, one predominant
site of 18F-FDG activity was transcutaneously identified
with the gamma probe within the anteriomedial left mid
thigh region. Surgical excision of the subcutaneous tissue
(measuring 16.0 × 7.0 × 3.0 cm in size) of this area was
undertaken. Post-excision evaluation of the excision bed
within this region was performed with the gamma probe
and revealed residual increased 18F-FDG activity above
background. Therefore, gamma probe directed excision of
additional deeper subcutaneous tissue (measuring 3.5 ×
2.0 × 1.0 cm in size) of this area was undertaken. Further
post-excision reevaluation of the excision bed within this
region was again performed with the gamma probe and
revealed no 18F-FDG activity above background.
Attention was then directed to the anterior lower one-
third of the left thigh region where the third hypermeta-
bolic focus was located in the subcutaneous tissues based
on the previous diagnostic whole body 18F-FDG PET/CT
scan. With the gamma probe, difficulty was encountered
transcutaneously distinguishing a finite site of 18F-FDG
activity that was distinct from that of the underlying back-
ground muscular and vascular blood pool 18F-FDG activ-
ity. Therefore, intraoperative ultrasound was performed
using a Hitachi HI VISION™ 6500 ultrasound system
(Hitachi Medical Systems America, Inc., Twinsburg, Ohio,
USA) with a variable frequency linear transducer EUP-
L54M (range 10.0 to 13.0 MHz) (Hitachi Medical Systems
America, Inc., Twinsburg, Ohio, USA). An 8 mm hypoe-
choic ultrasound lesion (Figure 2) was identified within
the subcutaneous tissues coinciding with the area of gen-
erally increase 18F-FDG activity within the anterior lower
one-third of the left thigh region seen on the previous
diagnostic whole body 18F-FDG PET/CT scan. More local-
ized increase 18F-FDG activity was verified within this
same region with the gamma probe and surgical excision
of subcutaneous tissue (measuring 4.2 × 4.0 × 1.0 cm in
size) of this area was undertaken. Post-excision evaluation
Intraoperative ultrasound showing an 8 mm hypoechoic  lesion identified within the subcutaneous tissues of an area of  generally increase 18F-FDG activity within the anterior lower  one-third of the left thigh region Figure 2
Intraoperative ultrasound showing an 8 mm hypoechoic 
lesion identified within the subcutaneous tissues of an area of 
generally increase 18F-FDG activity within the anterior lower 
one-third of the left thigh region.
Preoperative PET maximum intensity projection (A) and pre- operative cross sectional fused PET/CT images (B) of a  patient with recurrent metastatic melanoma to the left thigh Figure 1
Preoperative PET maximum intensity projection (A) and pre-
operative cross sectional fused PET/CT images (B) of a 
patient with recurrent metastatic melanoma to the left thigh. 
The preoperative PET/CT scan revealed three hypermeta-
bolic foci within the left thigh.World Journal of Surgical Oncology 2008, 6:1 http://www.wjso.com/content/6/1/1
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of the excision bed within this region was performed with
the gamma probe and revealed no 18F-FDG activity above
background. Ex vivo gamma probe evaluation revealed
increased 18F-FDG activity within the excised subcutane-
ous tissue. Likewise, ex vivo ultrasound evaluation
revealed the corresponding hypoechoic ultrasound lesion
within the excised subcutaneous tissue.
All three resected specimens were then transported to the
nuclear medicine department and imaged with the clini-
cal PET/CT scanner (Figure 3) at a time of approximately
210 minutes after the original 18F-FDG injection. Speci-
men PET/CT imaging revealed the presence of three
hypermetabolic foci, corresponding to the three sites of
excised subcutaneous tissue that represented the three
hypermetabolic areas in the subcutaneous tissues of the
left thigh region that were originally visualized on the pre-
operative diagnostic whole body 18F-FDG PET/CT scan.
The specimens were then transported back to the operat-
ing room in order to be sent to and processed by surgical
pathology for standard pathologic evaluation.
Postoperatively, the patient was recovered uneventfully in
the post-anesthesia care unit. After postoperative standard
stabilization and recovery (at a time of approximately 120
minutes after the completion of the surgical procedure
and at a time of approximately 340 minutes after the orig-
inal 18F-FDG injection), she was subsequently taken to the
nuclear medicine department and re-imaged with PET/CT
scan without administration of an additional dose of 18F-
FDG. The postoperative PET/CT scan demonstrated no
residual sites of hypermetabolic activity, verifying excision
of the all three previously visible sites of hypermetabolic
activity within the left thigh region (Figure 4).
Pathologic evaluation of the resected specimens revealed
three separate sites of malignant melanoma. This
included a 18 mm nodule of malignant melanoma that
corresponded to the first excised focus, representing the
larger of the two areas in the subcutaneous tissues of the
anteriomedial left mid thigh region which demonstrated
a peak SUV of 25.3 on the preoperative diagnostic whole
body 18F-FDG PET/CT scan. Likewise, an additional 8 mm
nodule of malignant melanoma was identified that corre-
Digital photograph of the three surgical specimens resected from the left thigh (A) Figure 3
Digital photograph of the three surgical specimens resected from the left thigh (A). Three dimensional CT reconstruction 
alone of the three surgical specimens from the left thigh (B). Three dimensional CT reconstruction of the three surgical speci-
mens from the left thigh fused with PET activity (C). Cross sectional specimen fused PET/CT images of the melanoma metas-
tases in the left thigh revealing three hypermetabolic foci (D).World Journal of Surgical Oncology 2008, 6:1 http://www.wjso.com/content/6/1/1
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sponded to the second excised focus, representing the
smaller of the two area in the subcutaneous tissues of the
anteriomedial left mid thigh region which demonstrated
a peak SUV of 25.3 on the preoperative diagnostic whole
body 18F-FDG PET/CT scan. Finally, a 6 mm nodule of
malignant melanoma was identified that corresponded to
the third excised focus, representing the area in the subcu-
taneous tissues of the anterior lower one-third of the left
thigh region which demonstrated a peak SUV of 3.4 on
the preoperative diagnostic whole body 18F-FDG PET/CT
scan.
At the time of the publication of this Technical Innova-
tions report, the patient is currently six months out from
the above-described innovative multimodality approach
for tumor localization and verification of resection of all
sites of hypermetabolic activity and appears to be without
any evidence of further disease.
Discussion
In the current Technical Innovations report, we describe a
case of occult recurrent metastatic melanoma that nicely
illustrates an innovative multimodality approach of peri-
operative  18F-FDG PET/CT imaging, intraoperative 18F-
FDG handheld gamma probe detection, and intraopera-
tive ultrasound for tumor localization and verification of
resection of all sites of hypermetabolic activity. It is our
contention [12-14], as well as others [7-11,15-17], that
the application of 18F-FDG-directed technology should be
utilized far-beyond its initial intention of diagnostic imag-
ing of patients at the time of the original evaluation and
should be applied to the operative arena for guiding the
surgical approach by providing the surgeon with real-time
intraoperative information on tumor location and verifi-
cation of tumor resection.
Several critical points with regards to this innovative mul-
timodality approach were brought to light in this particu-
lar case. First, the initial ability of diagnostic whole body
18F-FDG PET/CT imaging to identify, when conventional
techniques failed, the three site of hypermetabolic activity
was instrumental in allowing successful management of a
case of occult recurrent metastatic melanoma. Second,
intraoperative 18F-FDG gamma probe detection was able
to initially demonstrate the larger predominant hyper-
metabolic site of disease within the anteriomedial left mid
thigh region, After excision of this first predominant
hypermetabolic focus, the gamma probe was able to iden-
tify that the second smaller hypermetabolic focus was still
present, thus ultimately guiding successful excision of this
second smaller hypermetabolic focus. Third, intraopera-
tive ultrasound was critical in identifying the third site of
disease located within the anterior lower one-third of the
left thigh region which was less metabolically active and
which was not initially easily distinguishable from the
muscle and blood pools by intraoperative 18F-FDG
gamma probe detection. Fourth, the re-application of the
gamma probe after excision of the presumed third site of
disease located within the anterior lower one-third of the
left thigh region was critical to verifying that the ultra-
sound-detected lesion excised was, in fact, the third hyper-
metabolic focus of disease. Fifth, specimen PET/CT was
critical for verifying that each of the three surgically
resected tissue specimens contained the corresponding
sites of hypermetabolic activity seen on the original diag-
nostic whole body 18F-FDG PET/CT scan. Sixth, the imme-
diate postoperative PET/CT scan clearly demonstrated no
residual sites of hypermetabolic activity within the corre-
sponding excision beds, thus verifying excision of the all
three previously visible sites of hypermetabolic activity
within the left thigh region
Conclusion
The innovative multimodality approach of perioperative
18F-FDG PET/CT imaging, intraoperative 18F-FDG hand-
held gamma probe detection, and intraoperative ultra-
sound that is described in the current Technical
Innovations report is a promising combined technology
for aiding in tumor localization and verification of exci-
sion and may ultimately impact positively upon long-
term outcome of selected patients. Each component of
this innovative multimodality approach is technically fea-
sible and should be readily available to all practicing sur-
geons that have 18F-FDG capabilities at their medical
facilities. We strongly believe that the success of this inno-
vative multimodality approach will require the future
availability of some sort of portable PET/CT scanning
device within the operating room arena that would aid
significantly in the immediate, real-time intraoperative
verification of complete removal of all hypermetabolic
activity within the surgical resection field and would
Preoperative PET maximum intensity projection in the ante- rior projection view (A) and postoperative PET maximum  intensity projection in the anterior projection view (B) Figure 4
Preoperative PET maximum intensity projection in the ante-
rior projection view (A) and postoperative PET maximum 
intensity projection in the anterior projection view (B). The 
postoperative PET/CT scan revealed verification of resection 
of hypermetabolic foci previously noted on the preoperative 
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allow the surgeon to make further intraoperative deci-
sions about the need for additional surgical resection.
Abbreviations
18F-FDG, 18F-fluorodeoxyglucose; 
PET/CT, positron emission tomography/computed tom-
ography; 
SUV, standardized uptake value; 
MRI, magnetic resonance imaging.
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